Autolus Therapeutics (AUTL) said late Friday its Aucatzyl programmed T cell therapy has received marketing authorization from the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The safety of Aucatzyl includes a boxed warning for cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies, the company said.
Autolus said it is planning to produce the new medication at its manufacturing facility in the UK.
Shares of the company were up 1.9% in after-hours activity.
Price: 3.8001, Change: +0.07, Percent Change: +1.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。